Exelixis, Inc. (NASDAQ:EXEL) is among the Renaissance Technologies Portfolio: 10 Biggest Stocks. On September 17, Morgan Stanley raised the stock’s price target to $50 from $46, while maintaining an ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

In a report released today, from Roth MKM initiated coverage with a Buy rating on Exelixis and a price target of $47.00. The company’s shares closed yesterday at $39.14. Take advantage of TipRanks ...

Fantastic. Hi, everyone. Thank you so much for being here today. For those of you that don't know me, my name is Courtney Breen, I cover large-cap biopharma here at Bernstein. I have spent a little ...

Exelixis received a Hold rating and a $40.00 price target from Barclays analyst Etzer Darout on September 16. The company’s shares closed yesterday at $40.45. Take advantage of TipRanks Premium at 50% ...

On September 16, 2025, Adagene Inc. announced an amendment to its 2021 collaboration and license agreement with Exelixis, allowing Exelixis to use Adagene's SAFEbody technology platform to generate a ...